KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Treasury Shares: 2020-2025

  • Castle Biosciences' Treasury Shares was N/A to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year change of. This contributed to the annual value of $3.2 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Castle Biosciences reported Treasury Shares of $3.9 million as of Q3 2025, which was up 22.37% from $3.2 million recorded in Q4 2024.
  • In the past 5 years, Castle Biosciences' Treasury Shares ranged from a high of $3.9 million in Q3 2025 and a low of $1.1 million during Q4 2021.
  • Moreover, its 2-year median value for Treasury Shares was $3.6 million (2024), whereas its average is $3.6 million.
  • Data for Castle Biosciences' Treasury Shares shows a peak YoY surged of 550.36% (in 2021) over the last 5 years.
  • Castle Biosciences' Treasury Shares (Quarterly) stood at $1.1 million in 2021, then followed by $3.2 million in 2024, then followed by $3.9 million in 2025.
  • Its Treasury Shares stands at $3.9 million for Q3 2025, versus $3.2 million for Q4 2024 and $1.1 million for Q4 2021.